CVS · Earnings call · 2026Q2T · Full report

Specialty Pharmacy Market Position

CVS HEALTH Corp · 2026-08-05 · Importance 17 · Surprise 24

CVS Specialty is positioned as a leading specialty pharmacy serving complex patients across their full therapy journeys. Management attributes its differentiation to clinical expertise, data and analytics, personalized engagement, automation and AI-enabled processes that identify patients earlier and initiate therapy faster. CVS Specialty consistently achieves adherence above 90%, compared with an industry standard that competitors are working toward at 80%. Specialty pharmacy and a robust generic portfolio are expected to provide a key offset to pressure in other Pharmacy Services areas, while Cordavis’s Humira biosimilar has generated more than $1.8 billion in customer savings.

Key facts

• Cordavis biosimilar launch generated over $1.8 billion of savings on Humira for customers.
• CVS Specialty consistently operates above 90% adherence while industry standard target is 80%.